Activation of the GLP-1 Receptor Signalling Pathway: A Relevant Strategy to Repair a Deficient Beta-Cell Mass
Open accessThe DOI matches its Crossref record; 111 of the 111 references it cites were found in a registry or an index.
Abstract
Recent preclinical studies in rodent models of diabetes suggest that exogenous GLP-1R agonists and DPP-4 inhibitors have the ability to increase islet mass and preserve beta-cell function, by immediate reactivation of beta-cell glucose competence, as well as enhanced beta-cell proliferation and neogenesis and promotion of beta-cell survival. These effects have tremendous implication in the treatment of T2D because they directly address one of the basic defects in T2D, that is, beta-cell failure. In human diabetes, however, evidence that the GLP-1-based drugs alter the course of beta-cell function remains to be found. Several questions surrounding the risks and benefits of GLP-1-based therapy for the diabetic beta-cell mass are discussed in this review and require further investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 GLP-1 or Exendin-4 (Ex-4) activates beta-cells regeneration in vivo. The aim was to investigate in the rat model of neonatal beta-cell regeneration (nSTZ model), the capacity of in vivo treatments with GLP-1 or Ex-4 to promote beta-cell regeneration. To this end, nSTZ rats from the Wistar strain (W) were submitted to GLP-1 or Ex-4 administration from postnatal day 2 to day 6 only, and their beta-cell masses were tested on day 7 (a) and (b). In the nSTZ/GLP-1 and nSTZ/Ex-4 groups, total beta-cell masses per pancreas were both significantly increased (***P < .001) as compared with values in untreated nSTZ rats, representing, respectively, 51% and 71% of the control Wistar beta-cell mass, while nSTZ beta-cell mass represented only 21% of the control Wistar value. Beta-cell BrdU labeling index (c) in the untreated nSTZ rats was found to be significantly increased (P < .001) as compared with Wistar group. In the nSTZ/GLP-1 and nSTZ/Ex-4 groups, it was similarly increased. A representative figure is given with double immunostaining for BrdU and insulin in 7-day-old nSTZ rats (magnification ×1000). To estimate activation of neogenesis (d) and (e), the number of single beta-cells incorporated into the duct epithelium and the number of beta-cell clusters budding from ducts were quantified. The number of isolated beta-cell within pancreatic tissue of nSTZ rats represented 185% of Wistar value and the number of beta-cell buds in pancreatic tissue in nSTZ rats represented 106% of Wistar value. These two parameters were strongly increased in nSTZ/GLP-1 and nSTZ/Ex-4 rats as compared to untreated nSTZ rats (***P < .001). A representative figure is given with indirect immunoperoxydase staining for insulin in 7 day-old nSTZ/GLP-1 rats (magnification ×1000). Adapted from Tourrel et al. [83].](https://figures.cochat.ai/paper-figures/c544b531910d4ce2ba066166796bc3e4/activation-of-the-glp-1-receptor-signalling-pathway-a-relevant-strategy-to-figure-1.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This not only prevents the phosphorylation of JNK but also promotes the phosphorylation of STAT3, aiding the shift of macrophages to an anti-inflammatory M2 phenotype.327”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [327]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Specifically, activation of GLP-1R leads to an increase in cAMP levels, which in turn activates PKA, a widely regulating enzyme of cellular functions, capable of phosphorylating a variety of target proteins, thereby initiating the PKA/CREB signaling pathway.326,327”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [327]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes
Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., & Butler, P. C. (2003) · Diabetes · doi:10.2337/diabetes.52.1.102 · Cited by 4,011
Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP
de Rooij, J., Zwartkruis, F. J. T., Verheijen, M. H. G., Cool, R. H., Nijman, S. M. B., Wittinghofer, A., & Bos, J. L. (1998) · Nature · doi:10.1038/24884 · Cited by 1,969
A Family of cAMP-Binding Proteins That Directly Activate Rap1
Kawasaki, H., Springett, G. M., Mochizuki, N., Toki, S., Nakaya, M., Matsuda, M., Housman, D. E., & Graybiel, A. M. (1998) · Science · doi:10.1126/science.282.5397.2275 · Cited by 1,362
Xu, G., Stoffers, D. A., Habener, J. F., & Bonner-Weir, S. (1999) · Diabetes · doi:10.2337/diabetes.48.12.2270 · Cited by 1,209
Drucker, D. J., Philippe, J., Mojsov, S., Chick, W. L., & Habener, J. F. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.10.3434 · Cited by 903
IPF1, a homeodomain-containing transactivator of the insulin gene.
Ohlsson, H., Karlsson, K., & Edlund, T. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb06109.x · Cited by 888
The role of incretins in glucose homeostasis and diabetes treatment
Kim, W., & Egan, J. M. (2008) · Pharmacological Reviews · doi:10.1124/pr.108.000604 · Cited by 824 · cited 1×
“GLP-1R activation reduces beta-cell apoptosis in purified rodent and human islets as well as beta-cell lines after exposure to many cytotoxic agents, including reactive oxygen species, glucose, free fatty acid, palmitate, cytokines, tumor necrosis factor-α (TNF-α), immunosuppressive reagents, and dexamethasone [66].”
BackgroundRim is a putative Rab3 effector in regulating synaptic-vesicle fusion
Wang, Y., Okamoto, M., Schmitz, F., Hofmann, K., & Südhof, T. C. (1997) · Nature · doi:10.1038/41580 · Cited by 684
Holz IV, G. G., Kiihtreiber, W. M., & Habener, J. F. (1993) · Nature · doi:10.1038/361362a0 · Cited by 594
Glucagon-like Peptide-1 Receptor Signaling Modulates β Cell Apoptosis
Li, Y., Hansotia, T., Yusta, B., Ris, F., Halban, P. A., & Drucker, D. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209423200 · Cited by 589 · cited 1×
“A role for endogenous GLP-1 in prevention of beta-cell death was demonstrated by the increased susceptibility to streptozotocin-induced apoptosis in GLP-1R knockout mice; conversely, streptozotocininduced apoptosis was significantly reduced by coadministration of Ex-4 [67].”
Background
Research works printed but not linked: 6
- 10.1210/en.143.6.2303 · doi:10.1210/en.143.6.2303
- 10.1210/en.142.3.1218 · doi:10.1210/en.142.3.1218
- 2000, Journal of Clinical Endocrinology and Metabolism, 85, 3892
- 10.1002/(SICI)1097-4652(199912)181:3<470::AID-JCP11>3.0.CO;2-P · DOI · Paper page
- 2002, American Journal of Physiology, 283, E745
- 2008, The New England Journal of Medicine, 358, 1970
Cited by
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
Signaling pathways in obesity: mechanisms and therapeutic interventions
Wen, X., Zhang, B., Wu, B., Xiao, H., Li, Z., Li, R., Xu, X., & Li, T. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01149-x · Cited by 410
Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function
Rowlands, J., Heng, J., Newsholme, P., & Carlessi, R. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00672 · Cited by 302
“AD rodent models chronically treated with the GLP-1 analog Val(8)glucagonlike peptide-1 caused modulation of neurotransmitter release, synaptic transmission (LTP) formation, and restoration of synaptic plasticity, as well as preventing impairment in the learning of new spatial tasks (328–330).”
BackgroundRegulation of Glucose Homeostasis by GLP-1
Nadkarni, P., Chepurny, O. G., & Holz, G. G. (2014) · Progress in Molecular Biology and Translational Science · doi:10.1016/b978-0-12-800101-1.00002-8 · Cited by 287
Jakubowicz, D., & Froy, O. (2013) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2012.07.008 · Cited by 246
Food protein-derived bioactive peptides in management of type 2 diabetes
Patil, P., Mandal, S., Tomar, S. K., & Anand, S. (2015) · European Journal of Nutrition · doi:10.1007/s00394-015-0974-2 · Cited by 231
Zhong, J., Rao, X., & Rajagopalan, S. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.09.012 · Cited by 208
Diabetes and beta cell function: from mechanisms to evaluation and clinical implications
Cernea, S., & Dobreanu, M. (2013) · Biochemia Medica · doi:10.11613/bm.2013.033 · Cited by 203
Mayendraraj, A., ROSENKILDE, M. M., & Gasbjerg, L. S. (2022) · Peptides · doi:10.1016/j.peptides.2022.170749 · Cited by 183
Incretins: their physiology and application in the treatment of diabetes mellitus
Tasyurek, H. M., Altunbas, H. A., Balci, M. K., & Sanlioglu, S. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2501 · Cited by 121
“Analogues with amino acid or N-terminal group modi fi - cations, DPP-4-resistant agonists and fusion proteins conjugating GLP-1 to other peptides have been developed to prolong the plasma half-life of GLP-1 [34].”
BackgroundKapitza, C., Dahl, K., Jacobsen, J. B., Axelsen, M. B., & Flint, A. (2017) · Diabetologia · doi:10.1007/s00125-017-4289-0 · Cited by 126
Yu, M., Agarwal, D., Korutla, L., May, C. L., Wang, W., Griffith, N. N., Hering, B. J., Kaestner, K. H., Velazquez, O. C., Markmann, J. F., et al. (2020) · Nature Metabolism · doi:10.1038/s42255-020-0269-7 · Cited by 116
Review article: a comparison of glucagon‐like peptides 1 and 2
Janssen, P., Rotondò, A., Mulè, F., & Tack, J. F. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12092 · Cited by 130
Shah, P., Ardestani, A. D., Dharmadhikari, G., Laue, S., Schumann, D., Kerr-Conte, J. A., Pattou, F. N., Klein, T., & Maedler, K. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1029 · Cited by 108
Selective Ablation of Peptide YY Cells in Adult Mice Reveals Their Role in Beta Cell Survival
Sam, A. H., Gunner, D. J., King, A., Persaud, S. J., Brooks, L. J., Hostomska, K., Ford, H. E., Liu, B., Ghatei, M. A., Bloom, S. R., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.04.047 · Cited by 80
Kapodistria, K., Tsilibary, E.-P. C., Kotsopoulou, E. S., Moustardas, P., & Kitsiou, P. V. (2018) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13259 · Cited by 75
Recent advances in understanding the role of glucagon-like peptide 1
Reed, J., Bain, S., & Kanamarlapudi, V. (2020) · F1000Research · doi:10.12688/f1000research.20602.1 · Cited by 66
Oshaghi, E. A., Goodarzi, M. T., Higgins, V., & Adeli, K. (2017) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2017.1343274 · Cited by 68
Pandey, S., Mangmool, S., & Parichatikanond, W. (2023) · Pharmaceuticals · doi:10.3390/ph16060836 · Cited by 56
Oral Delivery of Glucagon-like Peptide-1 and Analogs: Alternatives for Diabetes Control?
Araújo, F., Fonte, P., Santos, H. A., & Sarmento, B. F. C. C. (2012) · Journal of Diabetes Science and Technology · doi:10.1177/193229681200600630 · Cited by 51
First-phase insulin secretion: can its evaluation direct therapeutic approaches?
Di Giuseppe, G., Ciccarelli, G., Soldovieri, L., Capece, U., Cefalo, C. M. A., Moffa, S., Nista, E. C., Brunetti, M., Cinti, F., Gasbarrini, A., et al. (2023) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2023.02.001 · Cited by 46
“GLP-1 RAs have several beneficial effects on β cell function, guaranteeing sustained glycemic control and preventing glucolipotoxicity [120,121].”
Ávila, D. L., de Araújo, G. R., Silva, M., Miranda, P. H. D. A., Diniz, M. F., Pedrosa, M. L., Silva, M. E., de Lima, W. G., & Costa, D. C. (2013) · Archives of Medical Research · doi:10.1016/j.arcmed.2013.03.004 · Cited by 46
Fu, Y., Yin, R., Guo, E., Cheng, R., Diao, X., Xue, Y., & Shen, Q. (2021) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.202000365 · Cited by 51
Direct cardiovascular effects of glucagon like peptide-1
Sheikh, A. (2013) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-5-47 · Cited by 45
Mechanisms of current therapies for diabetes mellitus type 2
Thulé, P. M. (2012) · AJP Advances in Physiology Education · doi:10.1152/advan.00094.2012 · Cited by 47
The complexity of signalling mediated by the glucagon-like peptide-1 receptor
Fletcher, M. M., Halls, M. L., Christopoulos, A., Sexton, P. M., & Wootten, D. L. (2016) · Biochemical Society Transactions · doi:10.1042/bst20150244 · Cited by 48
Tramutola, A., Arena, A., Cini, C., Butterfield, D. A., & Barone, E. (2016) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2017.1246183 · Cited by 42
Incretin-based therapies in prediabetes: Current evidence and future perspectives
Papaetis, G. S. (2014) · World Journal of Diabetes · doi:10.4239/wjd.v5.i6.817 · Cited by 41
Aly, H., Rohatgi, N., Marshall, C. A., Grossenheider, T. C., Miyoshi, H., Stappenbeck, T. S., Matkovich, S. J., & McDaniel, M. L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0066131 · Cited by 43
Menin and PRMT5 suppress GLP1 receptor transcript and PKA-mediated phosphorylation of FOXO1 and CREB
Muhammad, A. B., Xing, B., Liu, C., Naji, A., Ma, X., Simmons, R. A., & Hua, X. (2017) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00241.2016 · Cited by 34
Glucagon‐like peptide‐1: modulator of β ‐cell dysfunction and death
Rondas, D., D'Hertog, W., Overbergh, L., & Mathieu, C. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12165 · Cited by 32
Dutta, P. R., Bhansali, S., Kumar, V., Saikia, U., Medhi, B., Jha, V., & Bhansali, A. K. (2015) · The Indian Journal of Medical Research · doi:10.4103/0971-5916.162116 · Cited by 33
Harris, S., Blasio, M. J. D., Davis, M. A., Kelly, A. C., Davenport, H. M., Wooding, F. B. P., Blache, D., Meredith, D., Anderson, M. J., Fowden, A. L., et al. (2017) · The Journal of Physiology · doi:10.1113/jp273555 · Cited by 30
Körner, M., Rehmann, R., & Reubi, J. C. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2012.08.008 · Cited by 28
Lotfy, M. A., Singh, J., Rashed, H., Tariq, S., Zilahi, E., & Adeghate, E. A. (2014) · Cell and Tissue Research · doi:10.1007/s00441-014-1959-9 · Cited by 23
Nouri, M., Gargari, B. P., Tajfar, P., & Tarighat‐Esfanjani, A. (2022) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2022.102540 · Cited by 25
Subedi, L., Bamjan, A. D., Phuyal, S., Shim, J., Cho, S., Seo, J. B., Chang, K.-Y., Byun, Y., Kweon, S., & Park, J. W. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.12.039 · Cited by 22
Incretin Therapies Do Not Expand β-Cell Mass or Alter Pancreatic Histology in Young Male Mice
Cox, A. R., Lam, C. J., Rankin, M. M., Rios, J. S., Chavez, J., Bonnyman, C. W., King, K. B., Wells, R. A., Anthony, D., Tu, J. X., et al. (2017) · Endocrinology · doi:10.1210/en.2017-00027 · Cited by 19
Reed, J., Bain, S. C., & Kanamarlapudi, V. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s415934 · Cited by 24
Oh, C., Kohanim, S., Kong, F., Song, H., Huynh, N., Mendez, R., Chanda, M., Kim, E. E., & Yang, D. J. (2012) · Annals of Nuclear Medicine · doi:10.1007/s12149-011-0569-9 · Cited by 16
Yanto, T. A., Vatvani, A. D., Hariyanto, T. I., & Suastika, K. (2024) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2024.103069 · Cited by 12
Umpierrez, G. E., & Meneghini, L. (2013) · Endocrine Practice · doi:10.4158/ep12292.ra · Cited by 12
Zhang, Z., Li, J., Jiang, X., Yang, L., Lei, L., Cai, D.-H., Zhang, H., & Chen, H. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.2265 · Cited by 14
Vasu, S., Moffett, R. C., McCluskey, J. T., Hamid, M., Irwin, N., & Flatt, P. R. (2013) · Gene Therapy · doi:10.1038/gt.2013.33 · Cited by 12
Rowlands, J., Cruzat, V. F., Carlessi, R., & Newsholme, P. (2018) · Peptides · doi:10.1016/j.peptides.2017.11.015 · Cited by 14
Design of linear and cyclic peptide binders of different lengths from protein sequence informationPreprint
Li, Q., Vlachos, E. N., & Bryant, P. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.06.20.599739 · Cited by 12
Bertrand, R., Tolu, S., Picot, D., Tourrel‐Cuzin, C., Ouahab, A., Dairou, J., Deau, E., Lindberg, M. F., Meijer, L., Movassat, J., et al. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102242 · Cited by 13
Self-citationRISING STARS: Targeting G protein-coupled receptors to regulate energy homeostasis
Jamaluddin, A., & Gorvin, C. M. (2023) · Journal of Molecular Endocrinology · doi:10.1530/jme-23-0014 · Cited by 12
The beneficial effect of growth hormone treatment on islet mass in streptozotocin‐treated mice
Scheinman, E. J., Damouni, R., Caspi, A., Shen‐Orr, Z., Tiosano, D., & LeRoith, D. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2631 · Cited by 9
The role of glucagon-like peptides in osteosarcopenia
Tufail, E., Sanyal, S., Mithal, A., Sanyal, S., & Chattopadhyay, N. (2024) · Journal of Endocrinology · doi:10.1530/joe-24-0210 · Cited by 12
Mesto, N., Bailbé, D., Eskandar, M., Pommier, G., Gil, S., Tolu, S., Movassat, J., & Tourrel‐Cuzin, C. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30564 · Cited by 8
Self-citationCamacho-Ramírez, A., Gomar, D. A., Díaz-Gómez, A., Mateo-Gavira, I., Macías-Rodríguez, M. A., Pérez-Arana, G.-M., & Oliveira, J. A. P. (2019) · Tissue and Cell · doi:10.1016/j.tice.2019.02.008 · Cited by 5
Jonasson, M. E., Wicklow, B. A., Sellers, E. A. C., Dolinsky, V. W., & Doucette, C. A. (2015) · Biochemistry and Cell Biology · doi:10.1139/bcb-2015-0021 · Cited by 6
A novel gene therapy platform for the treatment of type 2 diabetes and obesity
Lourie, J., Goraltchouk, A., Hollander, J. M., BERGER, N. J. A., Rosen, H. G., Fujishiro, A. A., Luppino, F., Seregin, A., Rhym, L. H., & Zou, K. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102739 · Cited by 6
Targeting cardiometabolic risk in type 1 diabetes through incretin physiology
Frampton, R., HOCKING, S. L., SNAITH, J. R., & Greenfield, J. R. (2025) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2025.06.004 · Cited by 4
Ahmed, A. K. K., & Akl, M. M. (2024) · Advanced Pharmaceutical Bulletin · doi:10.34172/apb.2024.040 · Cited by 5
Murad, H. A. S., Saleh, H., Abdulaziz, G. S., Abdulsattar, M. A., & Ali, S. S. (2015) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-014-0278-8 · Cited by 6
Zahran, F. M., Nabil, A., Nassr, A., & Barakat, N. M. (2023) · Brazilian Journal of Biology · doi:10.1590/1519-6984.271731 · Cited by 3
GLP2-GLP2R signal affects the viability and EGFR-TKIs sensitivity of PC9 and HCC827 cells
Song, B., Ge, H., Pu, C., & Li, N. (2022) · BMC Pulmonary Medicine · doi:10.1186/s12890-021-01800-3 · Cited by 3
Vector-free in vivo trans-determination of adult hepatic stem cells to insulin-producing cells
Sarkar, S., Munshi, C., Chatterjee, S., Mukherjee, S., & Bhattacharya, S. (2019) · Molecular Biology Reports · doi:10.1007/s11033-019-04870-z · Cited by 3
Portha, B., Liu, J., Movassat, J., & Tourrel‐Cuzin, C. (2024) · Cahiers de Nutrition et de Diététique · doi:10.1016/j.cnd.2024.09.003 · Cited by 3
Self-citationIn vivo functional profiling and structural characterization of the human GLP1R A316T variant
Eid, L. E., Manchanda, Y., Austin, G. O., Deane-Alder, K., Rujan, R., Mariam, Z., Oqua, A. I., Belousoff, M. J., de la Serna, J. B., Sloop, K. W., et al. (2026) · Science Advances · doi:10.1126/sciadv.adw0899 · Cited by 9
Wang, X., Lu, G., Zhou, Y., & Zhao, G. (2026) · Journal of Endocrinological Investigation · doi:10.1007/s40618-026-02891-7 · Cited by 4
Extending the Reach of Exendin-4: New Pathways in the Control of Body Weight and Glucose Homeostasis
Good, D. J. (2012) · Endocrinology · doi:10.1210/en.2012-1149 · Cited by 2
Hassan, A. K., Zaatary, I. E., Hamed, S., & Abbas, O. A. (2019) · doi:10.35841/2320-9585.7.46-54 · Cited by 2
Hu, L., Zhang, Y., Wang, H., Peng, X.-Y., & Wang, Y. (2016) · Chinese Chemical Letters · doi:10.1016/j.cclet.2016.05.023 · Cited by 2
In vivo functional profiling and structural characterisation of the human Glp1r A316T variantPreprint
Eid, L. E., Deane-Alder, K., Rujan, R., Mariam, Z., Oqua, A. I., Manchanda, Y., Belousoff, M. J., de la Serna, J. B., Sloop, K. W., Rutter, G. A., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.19.619191 · Cited by 2
EL-SABBAGH, M. S. L. M. D. D. T., & Abdallah, M. (2019) · The Medical Journal of Cairo University/The Medical Journal of Cairo University · doi:10.21608/mjcu.2019.53884 · Cited by 1
Portha, B., Liu, J., Movassat, J., & Tourrel‐Cuzin, C. (2025) · Cahiers de Nutrition et de Diététique · doi:10.1016/j.cnd.2025.05.006 · Cited by 1
Self-citationPortha, B., & Liu, J. (2026) · Cahiers de Nutrition et de Diététique · doi:10.1016/j.cnd.2026.01.001 · Cited by 1
Self-citationErbasan, E., Aliciaslan, M., Erendor, F., Şensoy, S., Cetin, B., Aydemir, M., & Şanlıoğlu, S. (2026) · Journal of Molecular Medicine · doi:10.1007/s00109-026-02690-w · Cited by 1
Association of dipeptidyl peptidase-4 with Alzheimer's disease: A new therapeutic prospect
Wang, X., Chen, L., Li, W., He, Z., & Hai-ying, J. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877241304673 · Cited by 1
Akl, M. M., & Ahmed, A. K. K. (2024) · Qeios · doi:10.32388/l6amnd · Cited by 2
Mulder, D. J., Heerspink, H. J. L., & Lefrandt, J. D. (2012) · Nederlands Tijdschrift voor Diabetologie · doi:10.1007/s12467-012-0002-6
High-Fat Programming of β-Cell Dysfunction
Cerf, M. E. (2014) · Springer eBooks · doi:10.1007/978-94-007-6884-0_3-6
Molecular regulation of hormone secretion, growth and apoptosis of GLP-1-producing cells
Kappe, C. (2012) · Figshare
Aragão, G. C. (2017) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2017.tde-09032017-123135
Kanamarlapudi, V. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.734616040.793572407
100 anni dopo l’insulina: cosa ancora non sappiamo della sua secrezione nel diabete di tipo 2
Giuseppe, G. D., Mezza, T., Cinti, F., & Giaccari, A. (2022) · il Diabete · doi:10.30682/ildia2201c
Recovery of isolated pancreatic isletsderived from gut leak-induced diabetes type ii mouse model
Soedarmanto, A. (2020) · Chula Digiverse · doi:10.58837/chula.the.2020.475 · Cited by 2
Ahmed, A. K. K., & Akl, M. M. (2023) · Qeios · doi:10.32388/g6uisp.2
GLP-1 analogue semaglutide regulates pancreatic beta-cell proliferation via PDX-1 expression control
Ming, L., Sun, J., Chu, X., & Wang, C. (2024) · Theoretical and Natural Science · doi:10.54254/2753-8818/46/20240399
Portha, B., & Liu, J. (2026) · Cahiers de Nutrition et de Diététique · doi:10.1016/j.cnd.2025.12.005 · Cited by 1
Self-citationRôle des récepteurs purinergiques P2 dans la plasticité fonctionnelle du pancréas endocrine
Mesto, N. (2022) · theses.fr (ABES) · doi:10.70675/6d88bb6dz7c74z4c62za55czd1c1c3de5085
Advances in proteomics research related to semaglutide: evidence from humans and animals
Jia, Q., Mu, H., Wang, Y., Gao, Z., & Gao, Z. (2026) · Journal of Endocrinological Investigation · doi:10.1007/s40618-026-02989-y
Metadata
- Authors
- Portha, B., Tourrel-Cuzin, C., & Movassat, J.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- Laboratoire B2PE (Biologie et Pathologie du Pancréas Endocrine), Unité BFA (Biologie Fonctionnelle et Adaptive), Equipe 1, Université Paris-Diderot et CNRS EAC 4413, Bâtiment BUFFON, 5ème étage, pièce 552A, 4, Rue Lagroua Weill Hallé, Case 7126, 75205 Paris Cedex 13, France
- Corresponding author
- Portha, Bernard
- ORCID
- Movassat, Jamileh
- Venue
- Experimental Diabetes Research
- Publisher
- Wiley
- Published
- 2011
- Volume
- 2011
- Pages
- 1-11
- ISSN
- 1687-5214 (ISSN-L)
- 1687-5303
- PMC
- PMC3118608
- OpenAlex
- W2091979481
- Cited by
- 85
- References
- 110
- Citations by year
- 2026: 6 · 2025: 5 · 2024: 11 · 2023: 5 · 2022: 6 · 2021: 2 · 2020: 4 · 2019: 4 · 2018: 3 · 2017: 6 · 2016: 3 · 2015: 4 · 2014: 6 · 2013: 9 · 2012: 11
- FWCI
- 1.50
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Experimental Diabetes Research (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Centre National de la Recherche Scientifique
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Keywords
- GLP-1 receptor agonists, DPP-4 inhibitors, beta-cell mass, beta-cell neogenesis, beta-cell proliferation, beta-cell survival, type 2 diabetes, islet mass
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Animals, Cell Transformation, Neoplastic, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Female, Humans, Middle Aged, Pancreatic Neoplasms, Pancreatitis, Signal Transduction, Receptors, Glucagon, Insulin-Secreting Cells, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.